CMB - Cambium Bio Limited

[System]

Regeneus is a Sydney based regenerative medicine company. Founded in August 2007, Regeneus develops and commercialises proprietary cell-based technologies for the creation and manufacture of innovative cell treatments for humans and animals.

Regeneus' cell technologies enable the application of regenerative capacities of adipose derived cells (cells derived from fat) including mesenchymal stem cells (MSCs) for the treatment of musculoskeletal and other inflammatory conditions.

http://www.regeneus.com.au

 

[SuperGlue]

Anyone watching this one.

Stem Cell Company & cancer med. for animals. SP already moving.
Another one for the bottom drawer.

http://www.asx.com.au/asxpdf/20131114/pdf/42kv59vhq7jxpx.pdf

 

[SuperGlue]

Link to a write up for Biotech stocks:

http://www.thebull.com.au/premium/a/42153-7-biotech-stocks-with-bounding-share-prices.html


Please DYOR.

 

[greggles]

Regeneus gets US patent for Progenza and is in advanced negotiations with potential clinical licensees of Progenza for Japan.

Regeneus announces United States Patent Office decision to allow patent for Progenza

Sydney, Australia – 10 July 2018

Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza.

Issuance of the patent for United States Patent Application No. 14/342479 entitled 'Therapeutics using adipose cells and cell secretions' will provide commercial rights in the United States through to 2032. Corresponding patents have been granted in Australia and Japan and are being pursued for grant in other key territories including Europe.

Progenza is the company's lead cell therapy technology platform being developed for the treatment of osteoarthritis and other musculoskeletal diseases. It has the potential to be used for other inflammatory diseases that have limited treatment options. Progenza is made from expanded allogeneic mesenchymal stem cells (MSCs) from human adipose tissue and contains the bioactive secretions of the cells. Progenza cells work by secreting cytokines, growth factors and exosomes to reduce inflammation and pain and promote healing and repair in the damaged or diseased tissue. It is a scalable technology that has the demonstrated capability to produce millions of doses of cells from a single donor.

In December 2016, Regeneus announced a strategic collaboration and licensing agreement with AGC of Japan, a leading global biopharmaceutical manufacturer, for the exclusive rights to manufacture Progenza for all clinical applications in Japan. Regeneus is in advanced negotiations with potential clinical licensees of Progenza for Japan.

Regeneus has in excess of 70 patents or patent applications across multiple patent families which provides a substantial competitive advantage for the company’s product pipeline.

RGS share price up from 12c to 16c in the last few trading sessions.

 

[barney]

I imagine there could be a lot of stale Bulls holding this one given how long its been ranging around its lows … BUT

If the technology to help improve Osteoarthritis/Inflammation actually works it should move quickly once it hits the market

My main reservation at a glance were the very high Staff costs for the March Quarter. This added to the R and D + administration costs mean there is a high cash burn rate.

 

[System]

On April 10th, 2024, Regeneus Limited (RGS) changed its name and ASX code to Cambium Bio Limited (CMB).